As a phase 1 clinical trial, the goal is to learn more about the effects of investigational CT-0508 HER2 targeted treatment and determine if it is safe for people with HER2 overexpression in solid tumors.
Study TherapyIf you are eligible and choose to join, participation will last for about 1 year. If you qualify, you will be asked to do the following:
Receive Neupogen
Neupogen will be administered for 4 consecutive days to mobilize white blood cells.
Undergo a procedure called apheresis
Some of your white blood cells will be collected from your blood to make the study treatment.
Receive 1 dose divided into 1 to 3 infusions of the study treatment
Some participants may need to stay at the hospital while receiving the study treatment.
Visit the study clinic regularly for about 1 year
At each visit, you will undergo tests and assessments (such as physical exams & blood tests) and answer questions about your health.
Want more information about the study? Visit clinicaltrials.gov to learn more about the targeted HER2 clinical trial.
Find a Study Clinic